![Mark Gumbleton](https://profiles-cardiff.imgix.net/attachments/2917?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Professor Mark Gumbleton
Professor of Experimental Therapeutics and Head of School, School of Pharmacy and Pharmaceutical Sciences
School of Pharmacy and Pharmaceutical Sciences
Overview
Following undergraduate studies in Pharmacy and completion of professional registration, I undertook postgraduate studies and fellowships in Clinical Pharmacology and Biopharmaceutics at the University of Aberdeen Medical School, Cardiff University School of Pharmacy and the Medical Centre at the University of California, San Francisco.
After this I was appointed to the academic staff at the Universities of Strathclyde and Glasgow. Back in the USA I spent time as a visiting researcher at GeneMedicine Inc. before taking up an academic appointment at Cardiff University where I currently hold a professorial appointment.
Research activities include understanding at the whole body, tissue, cellular and molecular levels the interaction of experimental therapeutics with biological barriers, particularly the blood-brain-barrier. In experimental therapeutics I have a particular interest in cancer therapeutics with respect to brain tumours.
Qualifications
- Graduated BPharm (1982)
- Ph.D (1988) Biochemical Pharmacology and Pharmacokinetics (University of Wales)
- Professional Registration RPSGB (1983)
- Clinical Pharmacology specialisation (M.Sc) School of Medicine University of Aberdeen (1985)
- Postdoctoral fellowship and Research Specialist appointments in Biopharmaceutics and Clinical Pharmacology (University of California, San Francisco 1998-1992)
Publication
2022
- Powell, L. C. et al. 2022. Topical, immunomodulatory epoxy-tiglianes induce biofilm disruption and healing in acute and chronic skin wounds. Science Translational Medicine 14(662) (10.1126/scitranslmed.abn3758)
2021
- Alghamdi, M., Gumbleton, M. and Newland, B. 2021. Local delivery to malignant brain tumors: potential biomaterial-based therapeutic/adjuvant strategies. Biomaterials Science 9(18), pp. 6037-6051. (10.1039/D1BM00896J)
- Moriconi, C., Civita, P., Neto, C., Pilkington, G. J. and Gumbleton, M. 2021. Caveolin-1, a key mediator across multiple pathways in glioblastoma and an independent negative biomarker of patient survival. Frontiers in Oncology 11, article number: 701933. (10.3389/fonc.2021.701933)
- Biosca, A. et al. 2021. Zwitterionic self-assembled nanoparticles as carriers for Plasmodium targeting in malaria oral treatment. Journal of Controlled Release 331, pp. 364-375. (10.1016/j.jconrel.2021.01.028)
- Powell, L. C. et al. 2021. Quantifying the effects of antibiotic treatment on the extracellular polymer network of antimicrobial resistant and sensitive biofilms using multiple particle tracking. npj Biofilms and Microbiomes 7, article number: 13. (10.1038/s41522-020-00172-6)
2020
- Civita, P., Valerio, O., Naccarato, A. G., Gumbleton, M. and Pilkington, G. J. 2020. Satellitosis, a crosstalk between neurons, vascular structures and neoplastic cells in brain tumours; early manifestation of invasive behaviour. Cancers 12(12), article number: 3720. (10.3390/cancers12123720)
- El-Betany, A. M. M., Behiry, E. M., Gumbleton, M. and Harding, K. G. 2020. Humidified warmed CO2 treatment therapy strategies can save lives with mitigation and suppression of SARS-CoV-2 infection: an evidence review. Frontiers in Medicine 7, article number: 594295. (10.3389/fmed.2020.594295)
- Alghamdi, M. et al. 2020. Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme. Nanoscale Advances 2(10), pp. 4498-4509. (10.1039/D0NA00471E)
- Schirmer, L. et al. 2020. Heparin-based, injectable microcarriers for controlled delivery of interleukin-13 to the brain. Biomaterials Science 8(18), pp. 4997-5004. (10.1039/D0BM01249A)
- Brooks, O., Mikhail, A., Brown, C., Gumbleton, M., Jenkins, J. and Boyle, K. 2020. Sodium zirconium cyclosilicate for the treatment of persistent hyperkalaemia in prevalent haemodialysis patients: experience from clinical practice. Nephrology Dialysis Transplantation 35(S3), article number: P1299. (10.1093/ndt/gfaa142.P1299)
- Brooks, O., Mikhail, A., Brown, C., Gumbleton, M., Jenkins, J. and Boyle, K. 2020. Sodium zirconium cyclosilicate to prevent hyperkalaemia if haemodialysis is postponed due to vascular access complications: experience from clinical practice. Nephrology Dialysis Transplantation 35(S3), article number: P0324. (10.1093/ndt/gfaa142.P0324)
- El-Betany, A. M. et al. 2020. Auto-fluorescent PAMAM-based dendritic molecules and their potential application in pharmaceutical sciences. International Journal of Pharmaceutics 579, article number: 119187. (10.1016/j.ijpharm.2020.119187)
- Leite, D. M., Zvar Baskovic, B., Civita, P., Neto, C., Gumbleton, M. and Pilkington, G. J. 2020. A human co-culture cell model incorporating microglia supports glioblastoma growth and migration, and confers resistance to cytotoxics. The FASEB Journal 34(1), pp. 1710-1727. (10.1096/fj.201901858RR)
2019
- Matías, J. et al. 2019. Oral immunogenicity in mice and sows of enterotoxigenic escherichia coli outer-membrane vesicles incorporated into zein-based nanoparticles. Vaccines 8(1), article number: 11. (10.3390/vaccines8010011)
- Inchaurraga, L. et al. 2019. Modulation of the fate of zein nanoparticles by their coating with a Gantrez® AN-thiamine polymer conjugate. International Journal of Pharmaceutics: X 1, article number: 100006. (10.1016/j.ijpx.2019.100006)
- Brotons-Canto, A. et al. 2019. Mannosylated nanoparticles for oral immunotherapy in a murine model of peanut allergy. Journal of Pharmaceutical Sciences 108(7), pp. 2421-2429. (10.1016/j.xphs.2019.02.022)
- Abdulkarim, M., Sharma, P. K. and Gumbleton, M. 2019. Self-emulsifying drug delivery system: mucus permeation and innovative quantification technologies. Advanced Drug Delivery Reviews 142, pp. 62-74. (10.1016/j.addr.2019.04.001)
2018
- Bailey, D. M., Stacey, B. S. and Gumbleton, M. 2018. A systematic review and meta-analysis reveals altered drug pharmacokinetics in humans during acute exposure to terrestrial high altitude- clinical justification for dose adjustment?. High Altitude Medicine and Biology 19(2), pp. 141-148. (10.1089/ham.2017.0121)
- Menzel, C., Holzeisen, T., Laffleur, F., Zaichik, S., Abdulkarim, M., Gumbleton, M. and Bernkop-Schnürch, A. 2018. In vivo evaluation of an oral self-emulsifying drug delivery system (SEDDS) for exenatide. Journal of Controlled Release 277, pp. 165-172. (10.1016/j.jconrel.2018.03.018)
- Brotons-Canto, A., Gamazo, C., Martín-Arbella, N., Abdulkarim, M., Matías, J., Gumbleton, M. and Irache, J. M. 2018. Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy. International Journal of Biological Macromolecules 110, pp. 328-335. (10.1016/j.ijbiomac.2017.09.109)
- Bonengel, S. et al. 2018. Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. Journal of Controlled Release 273, pp. 21-29. (10.1016/j.jconrel.2018.01.012)
- Moriconi, C., Palmieri, V., Tornillo, G., Fillmore, H., Pilkington, G. J. and Gumbleton, M. 2018. Caveolin-1, a driver of invasive phenotype in in-vitro 3D-spheroid assays comprised of high grade GBM cells association with an AKT-inhibited phenotype. Neuro-Oncology 20(S1), pp. i13-i13. (10.1093/neuonc/nox238.058)
2017
- Price, D. F., Luscombe, C. N., Eddershaw, P. J., Edwards, C. D. and Gumbleton, M. 2017. The differential absorption of a series of P-glycoprotein substrates in isolated perfused lungs from Mdr1a/1b genetic knockout mice can be attributed to distinct physico-chemical properties: an insight into predicting transporter-mediated, pulmonary specific disposition. Pharmaceutical Research 34(12), pp. 2498-2516. (10.1007/s11095-017-2220-5)
- Morris, C. J., Aljayyoussi, G., Mansour, O., Griffiths, P. and Gumbleton, M. 2017. Endocytic uptake, transport and macromolecular interactions of anionic PAMAM dendrimers within lung tissue. Pharmaceutical Research 34(12), pp. 2517-2531. (10.1007/s11095-017-2190-7)
- Moriconi, C. et al. 2017. INSIDIA: a FIJI macro delivering high-throughput and high-content spheroid invasion analysis. Biotechnology Journal 12(10), article number: 1700140. (10.1002/biot.201700140)
- Ehrhardt, C. et al. 2017. Current progress toward a better understanding of drug disposition within the lungs: summary proceedings of the first workshop on drug transporters in the lungs. Journal of Pharmaceutical Sciences 106(9), pp. 2234-2244. (10.1016/j.xphs.2017.04.011)
- Paul, G., Gumbleton, M. and Somers, G. I. 2017. Effect of conditioning on rat lung function measurements and implications for exposure and dose estimation of inhaled drugs. Inhalation
- Moriconi, C., Palmieri, V., Tornillo, G., Fillmore, H., Pilkington, G. and Gumbleton, M. 2017. Caveolin-1 implicated as a pro-invasive gene in high-grade glioma cell models: implementation of a 3d spheroid matrix invasion assay. Neuro-Oncology 19(S1), pp. i21-i22. (10.1093/neuonc/now293.080)
2016
- Ulaeto, D. O., Morris, C. J., Fox, M. A., Gumbleton, M. and Beck, K. 2016. Destabilization of α-helical structure in solution improves bactericidal activity of antimicrobial peptides: Opposing effects on bacterial and viral targets. Antimicrobial Agents and Chemotherapy, article number: AAC.02146-15. (10.1128/AAC.02146-15)
- Williams, N. A. et al. 2016. Evidence of nonuniformity in urothelium barrier function between the upper urinary tract and bladder. Journal of Urology 195(3), pp. 763-770. (10.1016/j.juro.2015.10.066)
- Rohrer, J. et al. 2016. Mucus permeating thiolated self-emulsifying drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics 98, pp. 90-97. (10.1016/j.ejpb.2015.11.004)
- Gustavsson, L. et al. 2016. Chapter 6. Drug transporters in the lung: expression and potential impact on pulmonary drug disposition. In: Nicholls, G. and Youdim, K. eds. Drug Transporters : Volume 1: Role and Importance in ADME and Drug Development., Vol. 1. Royal Society of Chemistry, pp. 184.
2015
- Aljayyoussi, G., Price, D., Kreitmeyr, K., Keogh, J., Smith, M. W., Gumbleton, M. and Morris, C. J. 2015. Absorption of ipratropium and L-carnitine into the pulmonary circulation of the ex-vivo rat lung is driven by passive processes rather than active uptake by OCT/OCTN transporters. International Journal of Pharmaceutics 496(2), pp. 834-841. (10.1016/j.ijpharm.2015.10.036)
- Albaldawi, M., Agulló, N., Cattoz, B., Griffith, P., Bernkop-Schnürch, A., Borros, S. G. and Gumbleton, M. 2015. Nanoparticle diffusion within intestinal mucus: Three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles. European Journal of Pharmaceutics and Biopharmaceutics 97(Part A), pp. 230-238. (10.1016/j.ejpb.2015.01.023)
- Grießinger, J. et al. 2015. Methods to determine the interactions of micro- and nanoparticles with mucus. European Journal of Pharmaceutics and Biopharmaceutics 96, pp. 464-476. (10.1016/j.ejpb.2015.01.005)
- Campbell, L., Jasani, B., Griffiths, D. F. R. and Gumbleton, M. 2015. Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma. American Journal of Cancer Research 5(9), pp. 2838-2848.
- Williams, N. et al. 2015. Investigating detrusor muscle concentrations of oxybutynin after intravesical delivery in an Ex Vivo porcine model. Journal of Pharmaceutical Sciences 104(7), pp. 2233-2240. (10.1002/jps.24471)
2014
- Williams, N. et al. 2014. An ex Vivo investigation into the transurothelial permeability and bladder wall distribution of the nonsteroidal anti-inflammatory Ketorolac. Molecular Pharmaceutics 11(3), pp. 673-682. (10.1021/mp400274z)
2013
- Aljayyoussi, G. et al. 2013. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: A study in ex vivo lung models using chemical inhibition and genetic knockout. Journal of Pharmaceutical Sciences 102(9), pp. 3382-3394. (10.1002/jps.23587)
- Matthews, I. P., Gregory, C. J., Aljayyoussi, G., Morris, C. J., McDonald, I., Hoogendoorn, B. and Gumbleton, M. 2013. Maximal extent of translocation of single-walled carbon nanotubes from lung airways of the rat. Environmental Toxicology and Pharmacology 35(3), pp. 461-464. (10.1016/j.etap.2013.02.002)
- Aljayyoussi, G. and Gumbleton, M. 2013. A novel cost-effective approach for the efficient radiolabeling of dendritic macromolecules with a β-emitting radiotracer. Tetrahedron Letters 54(9), pp. 1045-1048. (10.1016/j.tetlet.2012.11.088)
- Campbell, L. et al. 2013. Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease. Journal of Translational Medicine 11(1), article number: 255. (10.1186/1479-5876-11-255)
2012
- Smith, M. W., Aljayyoussi, G. and Gumbleton, M. 2012. Peptide sequences mediating tropism to intact blood-brain barrier: An in vivo biodistribution study using phage display. Peptides 38(1), pp. 172-180. (10.1016/j.peptides.2012.06.019)
- Yildiz, A., John, E., Özsoy, Y., Araman, A., Birchall, J. C., Broadley, K. J. and Gumbleton, M. 2012. Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation. Journal of Controlled Release 162(2), pp. 456-463. (10.1016/j.jconrel.2012.07.008)
- Morris, C. J., Beck, K., Fox, M. . A., Ulaeto, D., Clark, G. C. and Gumbleton, M. 2012. Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery. Antimicrobial Agents and Chemotherapy 56(6), pp. 3298-3308. (10.1128/AAC.06335-11)
- Bowen, J. L., Kelly, M. A., Gumbleton, M., Davies, P. R. and Allender, C. J. 2012. A simple zero length surface-modification approach for preparing novel bifunctional supports for co-immobilisation studies. Tetrahedron Letters 53(29), pp. 3727-3730. (10.1016/j.tetlet.2012.04.116)
2011
- Morris, C. J., Smith, M. W., Griffiths, P. C., McKeown, N. B. and Gumbleton, M. 2011. Enhanced pulmonary absorption of a macromolecule through coupling to a sequence-specific phage display-derived peptide. Journal of Controlled Release 151(1), pp. 83-94. (10.1016/j.jconrel.2010.12.003)
- Gumbleton, M., Aljayyoussi, G., Crandon-Lewis, A. M., Francombe, D., Kreitmeyr, K., Morris, C. J. and Smith, M. W. 2011. Spatial expression and functionality of drug transporters in the intact lung: objectives for further research. Advanced Drug Delivery Reviews 63(1-2), pp. 110-118. (10.1016/j.addr.2010.09.008)
- Forbes, B. et al. 2011. Challenges in inhaled product development and opportunities for open innovation. Advanced Drug Delivery Reviews 63(1-2), pp. 69-87. (10.1016/j.addr.2010.11.004)
2010
- Gumbleton, M. and Jones, A. T. 2010. Cellular delivery of therapeutic macromolecules (CDTM) international Symposium 2010: lessons and progress from inter-disciplinary science. Drug Discovery Today 15(23-24), pp. 1079-180. (10.1016/j.drudis.2010.10.010)
- Thomas, N. B. P., Hutcheson, I. R., Campbell, L., Gee, J. M. W., Taylor, K. M., Nicholson, R. I. and Gumbleton, M. 2010. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Research and Treatment 119(3), pp. 575-591. (10.1007/s10549-009-0355-8)
- Griffiths, P. C., Occhipinti, P., Morris, C. J., Heenan, R. K., King, S. M. and Gumbleton, M. 2010. PGSE-NMR and SANS studies of the interaction of model polymer therapeutics with mucin. Biomacromolecules 11(1), pp. 120-125. (10.1021/bm9009667)
- Patton, J. S. et al. 2010. The particle has landed? characterizing the fate of inhaled pharmaceuticals. Journal of Aerosol Medicine and Pulmonary Drug Delivery 23(S2), pp. S71-S87. (10.1089/jamp.2010.0836)
- Aljayyoussi, G., Ford, W. R., McKeown, N. B. and Gumbleton, M. 2010. Differential transport of anionic PAMAM dendrimers across in vitro biological barriers [Abstract]. Drug Discovery Today 15(23-24), pp. 1114. (10.1016/j.drudis.2010.09.440)
- Barar, J., Gumbleton, M., Asadi, M. and Omidi, Y. 2010. Barrier functionality and transport machineries of human ECV304 cells. Medical Science Monitor 16(1), pp. BR52-BR60.
2009
- Campbell, L., Nuttall, R., Griffiths, D. F. R. and Gumbleton, M. 2009. Activated Extracellular Signal-Regulated Kinase Is an Independent Prognostic Factor in Clinically Confined Renal Cell Carcinoma. Cancer 115(15), pp. 3457-3467. (10.1002/cncr.24389)
- Endter, S., Francombe, D., Ehrhardt, C. and Gumbleton, M. 2009. RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. Journal of Pharmacy and Pharmacology 61(5), pp. 583-591. (10.1211/jpp/61.05.0006)
2008
- Campbell, L., Jasani, B., Edwards, K., Gumbleton, M. and Griffiths, D. F. R. 2008. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. British Journal of Cancer 98(5), pp. 931-940. (10.1038/sj.bjc.6604243)
- Campbell, L., Jasani, B., Gumbleton, M., Edwards, K. and Griffiths, D. F. 2008. Expression of 4EBP1 is an influential prognostic covariate in renal cell carcinoma [Abstract]. Modern Pathology 21(1s), pp. 150A., article number: 679. (10.1038/sj.modpathol.3801035)
- Omidi, Y., Barar, J., Ahmadian, S., Heidari, H. R. and Gumbleton, M. 2008. Characterization and astrocytic modulation of system L transporters in brain microvasculature endothelial cells. Cell Biochemistry and Function 26(3), pp. 381-391. (10.1002/cbf.1455)
2007
- Smith, M. W., Smith, J. W., Harris, C., Allender, C. J., Brancale, A. and Gumbleton, M. 2007. Phage display identification of functional binding peptides against 4-acetamidophenol (Paracetamol): An exemplified approach to target low molecular weight organic molecules. Biochemical and Biophysical Research Communications 358(1), pp. 285-291. (10.1016/j.bbrc.2007.04.122)
- Collins, E., Birchall, J. C., Williams, J. L. and Gumbleton, M. 2007. Nuclear localisation and pDNA condensation in non-viral gene delivery. The Journal of Gene Medicine 9(4), pp. 265-274. (10.1002/jgm.1015)
- Barar, J., Campbell, L., Hollins, A. J., Thomas, N. P., Smith, M. W., Morris, C. J. and Gumbleton, M. 2007. Cell selective glucocorticoid induction of caveolin-1 and caveolae in differentiating pulmonary alveolar epithelial cell cultures. Biochemical and Biophysical Research Communications 359(2), pp. 360-366. (10.1016/j.bbrc.2007.05.106)
- Smith, M. W., Omidi, Y. and Gumbleton, M. 2007. Primary porcine brain microvascular endothelial cells: Biochemical and functional characterisation as a model for drug transport and targeting. Journal of Drug Targeting 15(4), pp. 253-268. (10.1080/10611860701288539)
- Endter, S., Becker, U., Daum, N., Huwer, H., Lehr, C. M., Gumbleton, M. and Ehrhardt, C. 2007. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell and Tissue Research 328(1), pp. 77-84. (10.1007/s00441-006-0346-6)
2006
- Sakagami, M., Omidi, Y., Campbell, L., Kandalaft, L. E., Morris, C. J., Barar, J. and Gumbleton, M. 2006. Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung. Pharmaceutical research 23(2), pp. 270-279. (10.1007/s11095-005-9226-0)
- Smith, M. W. and Gumbleton, M. 2006. Endocytosis at the blood-brain barrier: From basic understanding to drug delivery strategies. Journal of Drug Targeting 14(4), pp. 191-214. (10.1080/10611860600650086)
2004
- Abulrob, A. N., Suller, M. T. E., Gumbleton, M., Simons, C. and Russell, A. D. 2004. Identification and biological evaluation of grapefruit oil components as potential novel efflux pump modulators in methicillin-resistant Staphylococcus aureus bacterial strains. Phytochemistry 65(22), pp. 3021-3027.
- Von Ruhland, C. J., Campbell, L., Gumbleton, M., Jasani, B. and Newman, G. R. 2004. Immunolocalization of caveolin-1 in rat and human mesothelium. Journal of Histochemistry & Cytochemistry 52(11), pp. 1415-1425. (10.1369/jhc.4A6334.2004)
2003
- Gumbleton, M., Kandalaft, L., McGuigan, C. and Siccardi, D. 2003. Stereoselective and concentration-dependent polarised epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: An in-vitro study in Caco-2 and MDCK cell monolayers. Journal of Pharmacology and Experimental Therapeutics 307(3), pp. 1112-1119. (10.1124/jpet.103.056135)
- Campbell, L., Gumbleton, M. and Griffiths, D. F. R. 2003. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. British Journal of Cancer 89(10), pp. 1909-1913. (10.1038/sj.bjc.6601359)
- Campbell, L., Abulrob, A. G., Kandalaft, L., Plummer, S., Hollins, A. J., Gibbs, A. and Gumbleton, M. 2003. Constitutive expression of P-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. Journal of Pharmacology and Experimental Therapeutics 304(1), pp. 441-452. (10.1124/jpet.102.042994)
- Jones, A. T., Gumbleton, M. and Duncan, R. 2003. Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. Advanced Drug Delivery Reviews 55(11), pp. 1353-1367. (10.1016/j.addr.2003.07.002)
2002
- Hollins, A. J., Campbell, L., Gumbleton, M. and Evans, D. J. R. 2002. Caveolin expression during chondrogenesis in the avian limb. Developmental Dynamics 225(2), pp. 205-211. (10.1002/dvdy.10143)
2001
- Birchall, J. C., Waterworth, C. A., Luscombe, C., Parkins, D. A. and Gumbleton, M. 2001. Statistical modelling of the formulation variables in non-viral gene delivery systems. Journal of Drug Targeting 9(3), pp. 169-184. (10.3109/10611860108997926)
2000
- Ramsay, E., Hadgraft, J., Birchall, J. C. and Gumbleton, M. 2000. Examination of the biophysical interaction between plasmid DNA and the polycations, polylysine and polyornithine, as a basis for their differential gene transfection in-vitro. International Journal of Pharmaceutics 210(1-2), pp. 97-107. (10.1016/S0378-5173(00)00571-8)
- Birchall, J. C., Marichal, C., Campbell, L., Alwan, A., Hadgraft, J. and Gumbleton, M. 2000. Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposome-plasmid DNA complexes. International Journal of Pharmaceutics 197(1-2), pp. 233-238. (10.1016/S0378-5173(00)00336-7)
- Birchall, J. C., Kellaway, I. W. and Gumbleton, M. 2000. Physical stability and in-vitro gene expression efficiency of nebulised lipid-peptide-DNA complexes. International Journal of Pharmaceutics 197(1-2), pp. 221-231. (10.1016/S0378-5173(00)00339-2)
1999
- Campbell, L., Hollins, A. J., Al-Eid, A., Newman, G. R., Von Ruhland, C. J. and Gumbleton, M. 1999. Caveolin-1 expression and caveolae biogenesis during cell transdifferentiation in lung alveolar epithelial primary cultures. Biochemical and Biophysical Research Communications 262(3), pp. 744-751. (10.1006/bbrc.1999.1280)
Articles
- Powell, L. C. et al. 2022. Topical, immunomodulatory epoxy-tiglianes induce biofilm disruption and healing in acute and chronic skin wounds. Science Translational Medicine 14(662) (10.1126/scitranslmed.abn3758)
- Alghamdi, M., Gumbleton, M. and Newland, B. 2021. Local delivery to malignant brain tumors: potential biomaterial-based therapeutic/adjuvant strategies. Biomaterials Science 9(18), pp. 6037-6051. (10.1039/D1BM00896J)
- Moriconi, C., Civita, P., Neto, C., Pilkington, G. J. and Gumbleton, M. 2021. Caveolin-1, a key mediator across multiple pathways in glioblastoma and an independent negative biomarker of patient survival. Frontiers in Oncology 11, article number: 701933. (10.3389/fonc.2021.701933)
- Biosca, A. et al. 2021. Zwitterionic self-assembled nanoparticles as carriers for Plasmodium targeting in malaria oral treatment. Journal of Controlled Release 331, pp. 364-375. (10.1016/j.jconrel.2021.01.028)
- Powell, L. C. et al. 2021. Quantifying the effects of antibiotic treatment on the extracellular polymer network of antimicrobial resistant and sensitive biofilms using multiple particle tracking. npj Biofilms and Microbiomes 7, article number: 13. (10.1038/s41522-020-00172-6)
- Civita, P., Valerio, O., Naccarato, A. G., Gumbleton, M. and Pilkington, G. J. 2020. Satellitosis, a crosstalk between neurons, vascular structures and neoplastic cells in brain tumours; early manifestation of invasive behaviour. Cancers 12(12), article number: 3720. (10.3390/cancers12123720)
- El-Betany, A. M. M., Behiry, E. M., Gumbleton, M. and Harding, K. G. 2020. Humidified warmed CO2 treatment therapy strategies can save lives with mitigation and suppression of SARS-CoV-2 infection: an evidence review. Frontiers in Medicine 7, article number: 594295. (10.3389/fmed.2020.594295)
- Alghamdi, M. et al. 2020. Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme. Nanoscale Advances 2(10), pp. 4498-4509. (10.1039/D0NA00471E)
- Schirmer, L. et al. 2020. Heparin-based, injectable microcarriers for controlled delivery of interleukin-13 to the brain. Biomaterials Science 8(18), pp. 4997-5004. (10.1039/D0BM01249A)
- Brooks, O., Mikhail, A., Brown, C., Gumbleton, M., Jenkins, J. and Boyle, K. 2020. Sodium zirconium cyclosilicate for the treatment of persistent hyperkalaemia in prevalent haemodialysis patients: experience from clinical practice. Nephrology Dialysis Transplantation 35(S3), article number: P1299. (10.1093/ndt/gfaa142.P1299)
- Brooks, O., Mikhail, A., Brown, C., Gumbleton, M., Jenkins, J. and Boyle, K. 2020. Sodium zirconium cyclosilicate to prevent hyperkalaemia if haemodialysis is postponed due to vascular access complications: experience from clinical practice. Nephrology Dialysis Transplantation 35(S3), article number: P0324. (10.1093/ndt/gfaa142.P0324)
- El-Betany, A. M. et al. 2020. Auto-fluorescent PAMAM-based dendritic molecules and their potential application in pharmaceutical sciences. International Journal of Pharmaceutics 579, article number: 119187. (10.1016/j.ijpharm.2020.119187)
- Leite, D. M., Zvar Baskovic, B., Civita, P., Neto, C., Gumbleton, M. and Pilkington, G. J. 2020. A human co-culture cell model incorporating microglia supports glioblastoma growth and migration, and confers resistance to cytotoxics. The FASEB Journal 34(1), pp. 1710-1727. (10.1096/fj.201901858RR)
- Matías, J. et al. 2019. Oral immunogenicity in mice and sows of enterotoxigenic escherichia coli outer-membrane vesicles incorporated into zein-based nanoparticles. Vaccines 8(1), article number: 11. (10.3390/vaccines8010011)
- Inchaurraga, L. et al. 2019. Modulation of the fate of zein nanoparticles by their coating with a Gantrez® AN-thiamine polymer conjugate. International Journal of Pharmaceutics: X 1, article number: 100006. (10.1016/j.ijpx.2019.100006)
- Brotons-Canto, A. et al. 2019. Mannosylated nanoparticles for oral immunotherapy in a murine model of peanut allergy. Journal of Pharmaceutical Sciences 108(7), pp. 2421-2429. (10.1016/j.xphs.2019.02.022)
- Abdulkarim, M., Sharma, P. K. and Gumbleton, M. 2019. Self-emulsifying drug delivery system: mucus permeation and innovative quantification technologies. Advanced Drug Delivery Reviews 142, pp. 62-74. (10.1016/j.addr.2019.04.001)
- Bailey, D. M., Stacey, B. S. and Gumbleton, M. 2018. A systematic review and meta-analysis reveals altered drug pharmacokinetics in humans during acute exposure to terrestrial high altitude- clinical justification for dose adjustment?. High Altitude Medicine and Biology 19(2), pp. 141-148. (10.1089/ham.2017.0121)
- Menzel, C., Holzeisen, T., Laffleur, F., Zaichik, S., Abdulkarim, M., Gumbleton, M. and Bernkop-Schnürch, A. 2018. In vivo evaluation of an oral self-emulsifying drug delivery system (SEDDS) for exenatide. Journal of Controlled Release 277, pp. 165-172. (10.1016/j.jconrel.2018.03.018)
- Brotons-Canto, A., Gamazo, C., Martín-Arbella, N., Abdulkarim, M., Matías, J., Gumbleton, M. and Irache, J. M. 2018. Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy. International Journal of Biological Macromolecules 110, pp. 328-335. (10.1016/j.ijbiomac.2017.09.109)
- Bonengel, S. et al. 2018. Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. Journal of Controlled Release 273, pp. 21-29. (10.1016/j.jconrel.2018.01.012)
- Moriconi, C., Palmieri, V., Tornillo, G., Fillmore, H., Pilkington, G. J. and Gumbleton, M. 2018. Caveolin-1, a driver of invasive phenotype in in-vitro 3D-spheroid assays comprised of high grade GBM cells association with an AKT-inhibited phenotype. Neuro-Oncology 20(S1), pp. i13-i13. (10.1093/neuonc/nox238.058)
- Price, D. F., Luscombe, C. N., Eddershaw, P. J., Edwards, C. D. and Gumbleton, M. 2017. The differential absorption of a series of P-glycoprotein substrates in isolated perfused lungs from Mdr1a/1b genetic knockout mice can be attributed to distinct physico-chemical properties: an insight into predicting transporter-mediated, pulmonary specific disposition. Pharmaceutical Research 34(12), pp. 2498-2516. (10.1007/s11095-017-2220-5)
- Morris, C. J., Aljayyoussi, G., Mansour, O., Griffiths, P. and Gumbleton, M. 2017. Endocytic uptake, transport and macromolecular interactions of anionic PAMAM dendrimers within lung tissue. Pharmaceutical Research 34(12), pp. 2517-2531. (10.1007/s11095-017-2190-7)
- Moriconi, C. et al. 2017. INSIDIA: a FIJI macro delivering high-throughput and high-content spheroid invasion analysis. Biotechnology Journal 12(10), article number: 1700140. (10.1002/biot.201700140)
- Ehrhardt, C. et al. 2017. Current progress toward a better understanding of drug disposition within the lungs: summary proceedings of the first workshop on drug transporters in the lungs. Journal of Pharmaceutical Sciences 106(9), pp. 2234-2244. (10.1016/j.xphs.2017.04.011)
- Paul, G., Gumbleton, M. and Somers, G. I. 2017. Effect of conditioning on rat lung function measurements and implications for exposure and dose estimation of inhaled drugs. Inhalation
- Moriconi, C., Palmieri, V., Tornillo, G., Fillmore, H., Pilkington, G. and Gumbleton, M. 2017. Caveolin-1 implicated as a pro-invasive gene in high-grade glioma cell models: implementation of a 3d spheroid matrix invasion assay. Neuro-Oncology 19(S1), pp. i21-i22. (10.1093/neuonc/now293.080)
- Ulaeto, D. O., Morris, C. J., Fox, M. A., Gumbleton, M. and Beck, K. 2016. Destabilization of α-helical structure in solution improves bactericidal activity of antimicrobial peptides: Opposing effects on bacterial and viral targets. Antimicrobial Agents and Chemotherapy, article number: AAC.02146-15. (10.1128/AAC.02146-15)
- Williams, N. A. et al. 2016. Evidence of nonuniformity in urothelium barrier function between the upper urinary tract and bladder. Journal of Urology 195(3), pp. 763-770. (10.1016/j.juro.2015.10.066)
- Rohrer, J. et al. 2016. Mucus permeating thiolated self-emulsifying drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics 98, pp. 90-97. (10.1016/j.ejpb.2015.11.004)
- Aljayyoussi, G., Price, D., Kreitmeyr, K., Keogh, J., Smith, M. W., Gumbleton, M. and Morris, C. J. 2015. Absorption of ipratropium and L-carnitine into the pulmonary circulation of the ex-vivo rat lung is driven by passive processes rather than active uptake by OCT/OCTN transporters. International Journal of Pharmaceutics 496(2), pp. 834-841. (10.1016/j.ijpharm.2015.10.036)
- Albaldawi, M., Agulló, N., Cattoz, B., Griffith, P., Bernkop-Schnürch, A., Borros, S. G. and Gumbleton, M. 2015. Nanoparticle diffusion within intestinal mucus: Three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles. European Journal of Pharmaceutics and Biopharmaceutics 97(Part A), pp. 230-238. (10.1016/j.ejpb.2015.01.023)
- Grießinger, J. et al. 2015. Methods to determine the interactions of micro- and nanoparticles with mucus. European Journal of Pharmaceutics and Biopharmaceutics 96, pp. 464-476. (10.1016/j.ejpb.2015.01.005)
- Campbell, L., Jasani, B., Griffiths, D. F. R. and Gumbleton, M. 2015. Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma. American Journal of Cancer Research 5(9), pp. 2838-2848.
- Williams, N. et al. 2015. Investigating detrusor muscle concentrations of oxybutynin after intravesical delivery in an Ex Vivo porcine model. Journal of Pharmaceutical Sciences 104(7), pp. 2233-2240. (10.1002/jps.24471)
- Williams, N. et al. 2014. An ex Vivo investigation into the transurothelial permeability and bladder wall distribution of the nonsteroidal anti-inflammatory Ketorolac. Molecular Pharmaceutics 11(3), pp. 673-682. (10.1021/mp400274z)
- Aljayyoussi, G. et al. 2013. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: A study in ex vivo lung models using chemical inhibition and genetic knockout. Journal of Pharmaceutical Sciences 102(9), pp. 3382-3394. (10.1002/jps.23587)
- Matthews, I. P., Gregory, C. J., Aljayyoussi, G., Morris, C. J., McDonald, I., Hoogendoorn, B. and Gumbleton, M. 2013. Maximal extent of translocation of single-walled carbon nanotubes from lung airways of the rat. Environmental Toxicology and Pharmacology 35(3), pp. 461-464. (10.1016/j.etap.2013.02.002)
- Aljayyoussi, G. and Gumbleton, M. 2013. A novel cost-effective approach for the efficient radiolabeling of dendritic macromolecules with a β-emitting radiotracer. Tetrahedron Letters 54(9), pp. 1045-1048. (10.1016/j.tetlet.2012.11.088)
- Campbell, L. et al. 2013. Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease. Journal of Translational Medicine 11(1), article number: 255. (10.1186/1479-5876-11-255)
- Smith, M. W., Aljayyoussi, G. and Gumbleton, M. 2012. Peptide sequences mediating tropism to intact blood-brain barrier: An in vivo biodistribution study using phage display. Peptides 38(1), pp. 172-180. (10.1016/j.peptides.2012.06.019)
- Yildiz, A., John, E., Özsoy, Y., Araman, A., Birchall, J. C., Broadley, K. J. and Gumbleton, M. 2012. Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation. Journal of Controlled Release 162(2), pp. 456-463. (10.1016/j.jconrel.2012.07.008)
- Morris, C. J., Beck, K., Fox, M. . A., Ulaeto, D., Clark, G. C. and Gumbleton, M. 2012. Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery. Antimicrobial Agents and Chemotherapy 56(6), pp. 3298-3308. (10.1128/AAC.06335-11)
- Bowen, J. L., Kelly, M. A., Gumbleton, M., Davies, P. R. and Allender, C. J. 2012. A simple zero length surface-modification approach for preparing novel bifunctional supports for co-immobilisation studies. Tetrahedron Letters 53(29), pp. 3727-3730. (10.1016/j.tetlet.2012.04.116)
- Morris, C. J., Smith, M. W., Griffiths, P. C., McKeown, N. B. and Gumbleton, M. 2011. Enhanced pulmonary absorption of a macromolecule through coupling to a sequence-specific phage display-derived peptide. Journal of Controlled Release 151(1), pp. 83-94. (10.1016/j.jconrel.2010.12.003)
- Gumbleton, M., Aljayyoussi, G., Crandon-Lewis, A. M., Francombe, D., Kreitmeyr, K., Morris, C. J. and Smith, M. W. 2011. Spatial expression and functionality of drug transporters in the intact lung: objectives for further research. Advanced Drug Delivery Reviews 63(1-2), pp. 110-118. (10.1016/j.addr.2010.09.008)
- Forbes, B. et al. 2011. Challenges in inhaled product development and opportunities for open innovation. Advanced Drug Delivery Reviews 63(1-2), pp. 69-87. (10.1016/j.addr.2010.11.004)
- Gumbleton, M. and Jones, A. T. 2010. Cellular delivery of therapeutic macromolecules (CDTM) international Symposium 2010: lessons and progress from inter-disciplinary science. Drug Discovery Today 15(23-24), pp. 1079-180. (10.1016/j.drudis.2010.10.010)
- Thomas, N. B. P., Hutcheson, I. R., Campbell, L., Gee, J. M. W., Taylor, K. M., Nicholson, R. I. and Gumbleton, M. 2010. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Research and Treatment 119(3), pp. 575-591. (10.1007/s10549-009-0355-8)
- Griffiths, P. C., Occhipinti, P., Morris, C. J., Heenan, R. K., King, S. M. and Gumbleton, M. 2010. PGSE-NMR and SANS studies of the interaction of model polymer therapeutics with mucin. Biomacromolecules 11(1), pp. 120-125. (10.1021/bm9009667)
- Patton, J. S. et al. 2010. The particle has landed? characterizing the fate of inhaled pharmaceuticals. Journal of Aerosol Medicine and Pulmonary Drug Delivery 23(S2), pp. S71-S87. (10.1089/jamp.2010.0836)
- Aljayyoussi, G., Ford, W. R., McKeown, N. B. and Gumbleton, M. 2010. Differential transport of anionic PAMAM dendrimers across in vitro biological barriers [Abstract]. Drug Discovery Today 15(23-24), pp. 1114. (10.1016/j.drudis.2010.09.440)
- Barar, J., Gumbleton, M., Asadi, M. and Omidi, Y. 2010. Barrier functionality and transport machineries of human ECV304 cells. Medical Science Monitor 16(1), pp. BR52-BR60.
- Campbell, L., Nuttall, R., Griffiths, D. F. R. and Gumbleton, M. 2009. Activated Extracellular Signal-Regulated Kinase Is an Independent Prognostic Factor in Clinically Confined Renal Cell Carcinoma. Cancer 115(15), pp. 3457-3467. (10.1002/cncr.24389)
- Endter, S., Francombe, D., Ehrhardt, C. and Gumbleton, M. 2009. RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. Journal of Pharmacy and Pharmacology 61(5), pp. 583-591. (10.1211/jpp/61.05.0006)
- Campbell, L., Jasani, B., Edwards, K., Gumbleton, M. and Griffiths, D. F. R. 2008. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. British Journal of Cancer 98(5), pp. 931-940. (10.1038/sj.bjc.6604243)
- Campbell, L., Jasani, B., Gumbleton, M., Edwards, K. and Griffiths, D. F. 2008. Expression of 4EBP1 is an influential prognostic covariate in renal cell carcinoma [Abstract]. Modern Pathology 21(1s), pp. 150A., article number: 679. (10.1038/sj.modpathol.3801035)
- Omidi, Y., Barar, J., Ahmadian, S., Heidari, H. R. and Gumbleton, M. 2008. Characterization and astrocytic modulation of system L transporters in brain microvasculature endothelial cells. Cell Biochemistry and Function 26(3), pp. 381-391. (10.1002/cbf.1455)
- Smith, M. W., Smith, J. W., Harris, C., Allender, C. J., Brancale, A. and Gumbleton, M. 2007. Phage display identification of functional binding peptides against 4-acetamidophenol (Paracetamol): An exemplified approach to target low molecular weight organic molecules. Biochemical and Biophysical Research Communications 358(1), pp. 285-291. (10.1016/j.bbrc.2007.04.122)
- Collins, E., Birchall, J. C., Williams, J. L. and Gumbleton, M. 2007. Nuclear localisation and pDNA condensation in non-viral gene delivery. The Journal of Gene Medicine 9(4), pp. 265-274. (10.1002/jgm.1015)
- Barar, J., Campbell, L., Hollins, A. J., Thomas, N. P., Smith, M. W., Morris, C. J. and Gumbleton, M. 2007. Cell selective glucocorticoid induction of caveolin-1 and caveolae in differentiating pulmonary alveolar epithelial cell cultures. Biochemical and Biophysical Research Communications 359(2), pp. 360-366. (10.1016/j.bbrc.2007.05.106)
- Smith, M. W., Omidi, Y. and Gumbleton, M. 2007. Primary porcine brain microvascular endothelial cells: Biochemical and functional characterisation as a model for drug transport and targeting. Journal of Drug Targeting 15(4), pp. 253-268. (10.1080/10611860701288539)
- Endter, S., Becker, U., Daum, N., Huwer, H., Lehr, C. M., Gumbleton, M. and Ehrhardt, C. 2007. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell and Tissue Research 328(1), pp. 77-84. (10.1007/s00441-006-0346-6)
- Sakagami, M., Omidi, Y., Campbell, L., Kandalaft, L. E., Morris, C. J., Barar, J. and Gumbleton, M. 2006. Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung. Pharmaceutical research 23(2), pp. 270-279. (10.1007/s11095-005-9226-0)
- Smith, M. W. and Gumbleton, M. 2006. Endocytosis at the blood-brain barrier: From basic understanding to drug delivery strategies. Journal of Drug Targeting 14(4), pp. 191-214. (10.1080/10611860600650086)
- Abulrob, A. N., Suller, M. T. E., Gumbleton, M., Simons, C. and Russell, A. D. 2004. Identification and biological evaluation of grapefruit oil components as potential novel efflux pump modulators in methicillin-resistant Staphylococcus aureus bacterial strains. Phytochemistry 65(22), pp. 3021-3027.
- Von Ruhland, C. J., Campbell, L., Gumbleton, M., Jasani, B. and Newman, G. R. 2004. Immunolocalization of caveolin-1 in rat and human mesothelium. Journal of Histochemistry & Cytochemistry 52(11), pp. 1415-1425. (10.1369/jhc.4A6334.2004)
- Gumbleton, M., Kandalaft, L., McGuigan, C. and Siccardi, D. 2003. Stereoselective and concentration-dependent polarised epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: An in-vitro study in Caco-2 and MDCK cell monolayers. Journal of Pharmacology and Experimental Therapeutics 307(3), pp. 1112-1119. (10.1124/jpet.103.056135)
- Campbell, L., Gumbleton, M. and Griffiths, D. F. R. 2003. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. British Journal of Cancer 89(10), pp. 1909-1913. (10.1038/sj.bjc.6601359)
- Campbell, L., Abulrob, A. G., Kandalaft, L., Plummer, S., Hollins, A. J., Gibbs, A. and Gumbleton, M. 2003. Constitutive expression of P-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. Journal of Pharmacology and Experimental Therapeutics 304(1), pp. 441-452. (10.1124/jpet.102.042994)
- Jones, A. T., Gumbleton, M. and Duncan, R. 2003. Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. Advanced Drug Delivery Reviews 55(11), pp. 1353-1367. (10.1016/j.addr.2003.07.002)
- Hollins, A. J., Campbell, L., Gumbleton, M. and Evans, D. J. R. 2002. Caveolin expression during chondrogenesis in the avian limb. Developmental Dynamics 225(2), pp. 205-211. (10.1002/dvdy.10143)
- Birchall, J. C., Waterworth, C. A., Luscombe, C., Parkins, D. A. and Gumbleton, M. 2001. Statistical modelling of the formulation variables in non-viral gene delivery systems. Journal of Drug Targeting 9(3), pp. 169-184. (10.3109/10611860108997926)
- Ramsay, E., Hadgraft, J., Birchall, J. C. and Gumbleton, M. 2000. Examination of the biophysical interaction between plasmid DNA and the polycations, polylysine and polyornithine, as a basis for their differential gene transfection in-vitro. International Journal of Pharmaceutics 210(1-2), pp. 97-107. (10.1016/S0378-5173(00)00571-8)
- Birchall, J. C., Marichal, C., Campbell, L., Alwan, A., Hadgraft, J. and Gumbleton, M. 2000. Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposome-plasmid DNA complexes. International Journal of Pharmaceutics 197(1-2), pp. 233-238. (10.1016/S0378-5173(00)00336-7)
- Birchall, J. C., Kellaway, I. W. and Gumbleton, M. 2000. Physical stability and in-vitro gene expression efficiency of nebulised lipid-peptide-DNA complexes. International Journal of Pharmaceutics 197(1-2), pp. 221-231. (10.1016/S0378-5173(00)00339-2)
- Campbell, L., Hollins, A. J., Al-Eid, A., Newman, G. R., Von Ruhland, C. J. and Gumbleton, M. 1999. Caveolin-1 expression and caveolae biogenesis during cell transdifferentiation in lung alveolar epithelial primary cultures. Biochemical and Biophysical Research Communications 262(3), pp. 744-751. (10.1006/bbrc.1999.1280)
Book sections
- Gustavsson, L. et al. 2016. Chapter 6. Drug transporters in the lung: expression and potential impact on pulmonary drug disposition. In: Nicholls, G. and Youdim, K. eds. Drug Transporters : Volume 1: Role and Importance in ADME and Drug Development., Vol. 1. Royal Society of Chemistry, pp. 184.
Research
Research interests
Hypothesis-driven science surrounding issues at the interface between the nature of biological barriers and experimental therapeutics.
The laboratory maintains a wide range of techniques ranging from cell and molecular biology through to ex-vivo and in-vivo models to address the scientific issues.
There are two principle areas within the laboratory's research strategy: blood-brain-barrier and in the developing area of brain tumour research.
Brain
In collaboration with Professor Geoff Pilkington at the Brain Tumour Research Centre of Excellence at Portsmouth University the laboratory in Cardiff is undertaking brain tumour research, with particular focus on gliomas and the cancer stem cell phenotype.
Malignant gliomas display an ability to invade into healthy brain tissue and to resist drug and radiation treatments. The features of advanced glioma suggest this tumour type possesses enhanced cancer stem cell (CSC)-like characteristics.
The CSC theory considers tumours to comprise heterogeneous cell populations with varying capacities for self-renewal, proliferation and invasion. One or more of these subpopulations act as cancer-initiating cells responsible for tumour initiation and perpetuation. The specific targeting of CSCs offers the potential to effectively eliminate tumours of drug-resistant and metastatic cell populations.
Blood Brain Barrier
In collaboration with major European networks and industry this area of work is focused on biological barriers and specifically the blood-brain-barrier (BBB). The lab is involved in exploring the interactions of the cell types within the neurovascular unit, and determining mechanisms by which therapeutic macromolecules, peptides and supramolecular structures, e.g. nanoparticles, may permeate the BBB to access brain parenchyma. This includes the design novel entities.
Current research projects
| Title | Investigator(s) | Funded | Dates | Amount (£) |
|---|---|---|---|---|
| Mucus permeating nanoparticulate drug delivery systems (ALEXANDER) | Prof M Gumbleton (PHRMY) (PI) | Commission of the European Communities | 01/03/12 - 28/04/16 | £179,162 |
| Caveolin-1 and Glioma Tumour Initiator Cells | Prof M Gumbleton (PHRMY) (PI) | Cancer Research Wales | 01/10/14 - 01/10/18 | £114,896 |
| Needle-free administration and targeted delivery of biophamaceuticals through smart engineering and novel formulations | Prof M Gumbleton (CI) | Commission of the European Communities | 01/11/12 - 31/10/17 | £171,418 |
Teaching
Current teaching profile
- PH1121 Molecule to patient
- PH1122 The role of the pharmacist in professional practice
- PH1125 Chemical and biological propertiesof drug molecules
- PH2110 Clinical & professionalpharmacy
- PH2203 Drug disposition
- PH3110 Optimisation of pharmaceutical care
- PH3113 Diseases and drugs II
- PH3202 Research methodology
- PH4116 Pharmacy research or scholarship project
- PH4118 Pharmaceutical sciences, pharmacy practice and the patient
Biography
Currently Executive Editor for Advanced Drug Delivery Reviews, a journal publishing high quality thematic reviews on a wide range of Advanced Drug Delivery topics.
Also on the editorial board of the Journal of Drug Targeting and International Journal of Nanomedicine.
I have published over:
- 90 full-length peer reviewed research publications
- 20 journal series, authored textbook chapters or edited books
- 116 conference abstracts or editorials.
I have supervised 25 successful PhD students and 24 postdoctoral/visiting scientists.
I have served on a number of pan-European scientific steering committees in drug delivery and as organiser/ scientific programme organiser for International scientific meetings. I also serve as a consultant to pharmaceutical industry in USA and UK and is Director of Research at the School of Pharmacy and Pharmaceutical Sciences, Cardiff University.
Supervisions
Current supervision
Dalal Alablani
Research student
Contact Details
Gumbleton@cardiff.ac.uk
+44 29208 75449
Redwood Building, Room Room 2.20, King Edward VII Avenue, Cardiff, CF10 3NB
+44 29208 75449
Redwood Building, Room Room 2.20, King Edward VII Avenue, Cardiff, CF10 3NB
